Roca Therapeutics

First-in-Class Drugs against ocular diseases driven by hyper-vascularization and chronic inflammation Revolutionizing severe retinal disease care with topical therapy & saving lives with groundbreaking treatments for uveal melanoma Created in 2021 and located in Nice (France), Roca Therapeutics is a spin-off from Nice University and SATT Sud Est, incubated by the PACA-Est incubator. Roca has an internationally recognized team of Directors and Advisors with a strong track record of Translational Research and Drug Development in Oncology, Ophtalmology and Immunology. Roca Therapeutics is surrounded by several local and national strategic partners: IRCAN, ICN, Centre Antoine Lacassagne, CNRS, University Côte d’Azur, SATT Sud-Est, Canceropole PACA, Incubator Paca-Est, Eurobiomed, … Roca Therapeutics has been rewarded by recognized prizes: i-Lab, bpifrance BFTE, PIA3, Amgen Prize, … Roca Therapeutics is founded by a lead corporate VC and has been backed by several non-dilutive financings. In October 2022, Roca Therapeutics completes seed funding round. Our mission is to revolutionize eye care with innovative, non-invasive treatments, giving patients a brighter, clearer vision of life.